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Abstract The biosynthesis of syringomycin (SR) and syringo-
peptin 22 (SP22), bioactive lipodepsipeptides of the phytopatho-
genic bacterium Pseudomonas syringae pv. syringae, was studied
by feeding 14C-labeled precursors to chloramphenicol-containing
bacterial suspensions. The preferential sites of incorporation
were determined by comparing the specific activities of the intact
radiolabeled metabolites and their single structural elements,
obtained by hydrolytic degradation followed by derivatization
and isolation by high performance liquid chromatography.
The results show that, upon feeding L-[14C(U)]-Thr, 35.0 and
31.0% of the SR radioactivity is retained in 2,3-dehydro-2-
aminobutyric acid (Dhb) and 4-chlorothreonine (Thr(4-Cl)),
respectively. L-[14C(U)]-Asp labels the same sites, though less
efficiently, and is also incorporated in 2,4-diaminobutyric acid
(Dab) and 3-hydroxyaspartic acid (Asp(3-OH)). Dhb is also
labeled by Thr and Asp in SP22. These are the first data on the
biosynthetic origin of the modified residues in P. syringae
lipopeptides.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Syringomycin (SR) [1,2] and syringopeptin 22 (SP22) [3] are
extracellular secondary metabolites produced in vitro by sev-
eral strains of the phytopathogenic bacterium Pseudomonas
syringae pv. syringae. As shown in Fig. 1, these peptides share
some structural features, like a lactone macrocycle and a me-
dium length chain hydroxylated lipid moiety. Both are pro-
duced as mixtures of homologous forms di¡ering in the length
of the acyl chain. Following their isolation and structural
elucidation, analogous investigations, extended to other
strains of the bacterium, led to the discovery of a number
of new metabolites. P. syringae lipopeptides known so far
can be classi¢ed into two groups on the basis of their struc-
ture and biological activities. The ¢rst comprises, besides SR,
other nine amino acid residues-containing lipopeptide lactones
characterized by strong anti-fungal activity [4], like syringo-
toxin [5], syringostatin [2] and pseudomycin [6], each pro-
duced by a di¡erent strain. The second group comprises phy-
totoxic and anti-bacterial compounds [4] with a larger peptide
moiety of 22 or 25 residues. These include SP22 [3] and its
isoforms [7,8] as well as two SP25 isoforms [3,9]. Like most
bacterial peptide metabolites, they contain several uncommon
amino acids. For example, 2,4-diaminobutyric acid (Dab) and
the C-terminal tripeptide 2,3-dehydroamino-butyroyl-3-hy-
droxyaspartyl-4-chlorothreonine (Dhb-Asp(3-OH)-Thr(4-Cl))
are conserved in all the lipodepsinonapeptides. Dhb and
Dab are also contained in SPs.
Intensive investigations into the biological activities of these
metabolites, recently reviewed [10], are aimed at understand-
ing their role in plant pathogenesis and the development of
medical and biotechnological applications. Studies of their
mechanism of action in vitro demonstrated that the disruption
of cell membrane integrity lies at the basis of their biocidal
action on plant, animal and microbial cells. However, the
di¡erent toxicity of the two types of lipopeptides towards
various biological systems suggests that the interaction with
lipid bilayers could be only part of a more complex process
and that speci¢c events, in which the role of the modi¢ed
amino acids should be considered, could take place in the
mechanism of action of each particular system. Besides
Thr(4-Cl), whose relevance, but not function, in the anti-fun-
gal activity of lipodepsinonapeptides has been demonstrated
[11], P. syringae metabolites contain various other amino
acids which have been implicated in the biological activity
in di¡erent systems. For example, Asp(3-OH) and Dab were
shown to possess antibiotic and neurotoxic activity, respec-
tively [12,13]. Moreover, 2,3-unsaturated residues were shown
to contribute to the anti-microbial property of the compounds
that contain them [14,15].
The interesting chemical structures and the vast array of
biological activities of P. syringae pv. syringae lipodepsipep-
tides, as well as the signi¢cant agricultural damage caused by
this phytopathogenic organism, motivated us to study the
biosynthesis of this group of peptide secondary metabolites.
We have shown previously [16] that the thiotemplate mecha-
nism of peptide synthesis [17] operates in the formation of SR
and SP22. In previous studies, the entire SR biosynthetic gene
cluster was sequenced and the role of some domains was
demonstrated biochemically [18]. Here, we present the evi-
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dence on the biosynthetic precursors of four modi¢ed amino
acids in P. syringae lipopeptides.
2. Materials and methods
2.1. Preparation of SR and SP
P. syringae pv. syringae strain B301D-R was grown in 1l Roux
bottles as previously described [11]. The mixtures of the secondary
metabolites were extracted from the culture broth and isolated by
reversed phase-high performance liquid chromatography (RP-
HPLC) on an Aquapore RP 300 column (4.6U250 mm, 7 Wm, Ap-
plied Biosystems), using a Beckman System Gold 126 instrument
under conditions described in [11].
SR and SP22 obtained from the appropriate HPLC fractions were
lyophilized, redissolved in water and quanti¢ed by measuring the ab-
sorbance at 220 nm (O= 30 000 and O= 140 000 M31 cm31, respec-
tively). A calibration curve was constructed for each metabolite using
samples quanti¢ed by amino acid analysis after hydrolysis. Radioac-
tivity was determined by scintillation counting on a LKB Wallac 1211
instrument.
2.2. Incubation experiments
Chloramphenicol was added to 24 h old bacterial cultures to a ¢nal
concentration of 0.1 mg/ml. The radioactive precursors, L-[14C(U)]-
Val or L-[14C(U)]-Thr (244 mCi/mmol), or L-[14C(U)]-Asp (224.8
mCi/mmol), all purchased from Du Pont de Nemour and previously
diluted with unlabeled carrier material, were subsequently added.
After 120 h of incubation at 25‡C, the metabolites were extracted
and puri¢ed to constant speci¢c radioactivity as described in [11].
2.3. Chemical methods
The mixtures of the amino acids obtained by hydrolysis with HCl
6 N (24 h, 110‡C) of radiolabeled lipodepsipeptides were derivatized
with 2,4-dinitro£uorobenzene (DNFB) [19] and with 2,4-dinitrophe-
nylhydrazine [20]. The dinitrophenyl (DNP) amino acids were fractio-
nated by RP-HPLC on a C18 column, 4.6U250 mm, 5 Wm (Beckman,
Ultrasphere), and eluted with a gradient of solvent A (KH2PO4,
25 mM, pH 6.8) and solvent B (acetonitrile:2-propanol, 3:1) at a
£ow rate of 1.0 ml/min. The gradient program was as follows: the
initial concentration, 7% solvent B, constant for 1 min, changed lin-
early to 23% in 30 min. After 1 min of isocratic elution, the concen-
tration of B reached 60% in 12 min and after 1 min, the initial con-
ditions were restored. The 2,4-dinitrophenylhydrazone (DNPH) of
2-oxobutyric acid was isolated by RP-HPLC under conditions de-
scribed in [11]. The derivatives were quanti¢ed by measuring the ab-
sorbance at 360 nm (O= 12 235 and O= 21 033 M31 cm31 for mono-
and diamino acids, respectively; O= 25 600 M31 cm31 for DNPH of
2-oxobutyric acid) and their radioactivity was measured. Thr(4-Cl)
was obtained by hydrolyzing its derivative N-Cbz-Thr(4-Cl) methyl
ester, prepared from the corresponding vinylglycine derivative as de-
scribed in [21]. The latter was synthesized starting from glutamic acid
according to Hanessian’s procedure [22].
3. Results
3.1. Production of [14C]SR and [14C]SP22
To establish the most suitable timing for the addition of the
radiolabeled precursors, the production of SR and SP22 in P.
syringae pv. syringae cultures was monitored during the bac-
terial growth. The data shown in Fig. 2 indicate that the
secretion of the two metabolites started during the logarithmic
growth phase and reached a maximum in the early stationary
phase. The peak of SP22 production was delayed, compared
to SR.
Twenty-four hours after the inoculation was subsequently
chosen as the most suitable time for the addition of a protein
synthesis inhibitor and a radiolabeled precursor. This repre-
sents a compromise between the amount of cells, su⁄cient to
ensure further observable production of the metabolites, and
the amount of lipodepsipeptides produced at the time of feed-
ing (3.0 nmol/ml and 0.9 nmol/ml for SR and SP22, respec-
tively), in order to minimize the dilution of the labeled com-
pounds. In a typical feeding experiment, a precursor with a
speci¢c activity of 4.3U106 cpm/Wmol was administered to the
chloramphenicol-containing bacterial suspension. Initially, the
experiment with L-[14C(U)]-Val was run as control. As ex-
pected, this amino acid was incorporated into SP22 which
contains several valine residues (speci¢c molar incorporation
4.45%) but did not label signi¢cantly SR (speci¢c molar in-
corporation 0.83%), thus showing that the dispersion of the
label via degradative processes was negligible. Threonine and
aspartic acid were chosen as possible precursors because, on
the basis of the data presented in the literature [13,23], they
could be expected to be incorporated into Dhb and Dab. In
fact, by feeding L-[14C(U)]-Thr or L-[14C(U)]-Asp, lipodepsi-
peptides with speci¢c radioactivity in the range of 105 cpm/
Wmol were obtained. The speci¢c molar incorporations ranged
between 2 and 6%. The radioactive peptide metabolites were
diluted with unlabeled material prior to degradation.
3.2. Degradation of [14C]SR and [14C]SP22 and
determination of the labeling pattern
To determine the preferential sites of label incorporation,
the speci¢c radioactivity of the intact metabolite was com-
pared to that of the single amino acid residues. To achieve
this, a procedure suitable for the isolation of the latter was
deviced. Typically, the mixture obtained after hydrolysis of
Fig. 1. Structures of SR (a) and SP22 (b).
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[14C]SR was divided into two portions: one was treated with
2,4-dinitrophenylhydrazine, which allows us to derivatize
2-oxobutyric acid produced by deamination of Dhb [24],
and the other with DNFB, which is adequate suitable for
the derivatization of all the other residues. Following fractio-
nation of the DNP derivatives, all the amino acid residues and
their by-products formed during the course of the acid hydro-
lysis were separated and assigned by analyzing the elution
pro¢les of the derivatized hydrolysis mixtures of each amino
acid present in SR. The results of the degradation studies of
samples of [14C]SR deriving from incubations with L-[14C(U)]-
Thr and L-[14C(U)]-Asp are summarized in Table 1. They
represent the average of the values obtained in three di¡erent
experiments. The speci¢c radioactivity of the Ser residue could
not be quanti¢ed because its DNP derivative co-eluted with
DNFB.
Radioactive threonine was incorporated essentially into
Dhb and Thr(4-Cl), which contained 35.0 and 31.0% of the
radioactivity of the intact SR, respectively, while the distribu-
tion of the label deriving from aspartic acid was more scat-
tered. It labeled Asp(3-OH) and Dab to a similar extent (13.2
and 15.9% of the SR radioactivity, respectively) and, in ac-
cordance with its role as a precursor of threonine, it was
incorporated, albeit less e⁄ciently, into the same residues la-
beled by Thr. For experiments with SP22, only the radioac-
tivity retained in Dhb was determined and shown to be 21.8
and 14.6% feeding labeled Thr and Asp, respectively.
4. Discussion
The degradation studies carried out on SR and SP22, pro-
duced upon feeding radiolabeled precursors, shed light on the
origin of some of the modi¢ed residues in these molecules.
The overview of the biosynthetic pathways is shown in Fig.
3. The level of radioactivity found in Dhb, in the experiments
with L-[14C(U)]-Thr, demonstrates that this modi¢ed amino
acid is formed by 2,3-dehydration of the corresponding 3-hy-
droxy acid. This con¢rms that the most frequently encoun-
tered route for the production of K,L-unsaturated amino acids
[25] also operates in P. syringae. The lower level of the label
retention in Dhb observed by feeding [14C]-Asp was expected
on the basis of the biochemical pathway that leads to threo-
nine from aspartate [26]. Conversely, the e⁄cient incorpora-
Fig. 2. Growth curve of P. syringae pv. syringae, strain B301D-R
(a), time course of the production of SR (F) and SP22 (R) (b).
Table 1
Distribution of 14C label in the single amino acid residues of [14C]SR, produced upon feeding L-[14C(U)]-Asp (a) and L-[14C(U)]-Thr (b) to P.
syringae pv. syringae (strain B301D-R) cell suspensions
Speci¢c activity (cpm/Wmol) % of SR radioactivity retained in the residues
(a) (b) (a) (b)
[14C]SR 7.00U104 4.50U104 100 100
[14C]DNP-Asp(3-OH) 0.92U104 0.14U104 13.2 3.1
[14C]DNP-Dab 1.11U104 0.06U104 15.9 1.4
[14C]DNP-Phe 0.10U104 0.06U104 1.4 1.4
[14C]DNP-Thr(4-Cl) 0.58U104 1.40U104 8.3 31.0
[14C]DNP-Arg 0.21U104 0.09U104 3.0 2.0
[14C]DNPH of 2-oxobutyric acid 1.36U104 1.58U104 19.5 35.0
Fig. 3. Schematic overview of the origin of Asp(3-OH), Dab, Dhb
and Thr(4-Cl).
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tion of radiolabeled threonine into its chlorinated analogue is
the ¢rst report on the biosynthetic origin of this uncommon
amino acid. The level of incorporation, similar to that ob-
served for Dhb, whose formation from Thr implies only one
reaction, suggests that threonine is a very close, if not the
direct, precursor of its chlorinated analogue. However, the
direct halogenation of this amino acid appears improbable
in the light of the present knowledge on the mechanism of
action of chloroperoxidases, enzymes involved in biological
halogenations. All the known haloperoxidases, classi¢ed into
three groups on the basis of the type of cofactor used, catalyze
the formation of an electrophilic form of chlorine which re-
quires an electron rich substrate [27^29]. Recently, an elegant
study on the formation of trichloroleucine in the marine cya-
nobacterial metabolite barbamide suggested a novel mecha-
nism of chlorination, possibly involving radicals [30]. Our
data point towards the role of threonine as direct precursor
of Thr(4-Cl) but do not allow us to rule out the 3,4-dehydra-
tion leading to vinylglycine, which would be a more suitable
substrate of the known chloroperoxidases, as reaction inter-
mediate. The identi¢cation of the biosynthetic precursors of
the modi¢ed residues is essential for the complete understand-
ing of a biosynthetic pathway. For example, our knowledge
on the role of Thr as precursor of Thr(4-Cl) was helpful in the
determination of the catalytic activity of the synthetase mod-
ule encoded by syrB1 [18].
The radioactivity derived from [14C]-Asp besides being in-
corporated, as expected, into residues whose nearer precursor
is threonine was also retained in Dab and Asp(3-OH). The
biosynthesis of Dab by transamination of aspartic semihalde-
hyde with glutamate has recently been demonstrated in Hal-
omonas elongata [31]. This three step pathway is compatible
with the level of incorporation observed in SR. The Asp(3-
OH) was shown to originate by direct hydroxylation of Asp in
the blood clotting cascade enzymes [32] and by the aldol type
condensation, between glycine and glyoxylate, in Micrococcus
denitri¢cans [33]. The results of our feeding experiments do
not clearly point towards a direct hydroxylation of Asp.
Nevertheless, they allow us to rule out the second route in
the biosynthesis of SR. Firstly, threonine, which is an inter-
mediate on the pathway from aspartate to glycine, should be a
better precursor than aspartate and the contrary is observed.
Moreover, the multistep sequence required to produce glycine
and glyoxylate from aspartic acid is not compatible with the
Asp(3-OH) radioactivity level measured (13.2% of the intact
metabolite). In fact, the scrambling of the label is re£ected in
approximately 3% of the radioactivity, as exempli¢ed by the
label retention level in Phe and Arg.
In conclusion, we determined the biosynthetic precursors
of four modi¢ed amino acids in SR, which are constituents
of all P. syringae lipodepsinonapeptides. Two of these resi-
dues, Dhb and Dab, are also contained in all SPs. It is rea-
sonable to assume that the conclusions of this investigation
can be extended to other structurally related Pseudomonas
metabolites.
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